Dyslipidemia resident survival guide: Difference between revisions
YazanDaaboul (talk | contribs) |
YazanDaaboul (talk | contribs) |
||
Line 30: | Line 30: | ||
{{familytree/start}} | {{familytree/start}} | ||
{{familytree | | | | | | | | | | | | A01 | | | | | | | | | | | | | | | | | | | | | | | | | | | | |A01='''Identify risk factors for CAD'''<br><br> | {{familytree | | | | | | | | | | | | A01 | | | | | | | | | | | | | | | | | | | | | | | | | | | | |A01=<div style="float: left; text-align: left; width: 18em; padding:1em;">'''Identify risk factors for CAD'''<br><br> | ||
'''''Major risk factors:'''''<br> | '''''Major risk factors:'''''<br> | ||
Line 80: | Line 80: | ||
❑ ApoE4 isoform<br> | ❑ ApoE4 isoform<br> | ||
❑ ↑ uric acid}} | ❑ ↑ uric acid</div>}} | ||
{{familytree | | | | | | | | | | | | |!| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |}} | {{familytree | | | | | | | | | | | | |!| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |}} | ||
{{familytree | | | | | | | | | | | | B01 | | | | | | | | | | | | | | | | | | | | | | | | | | | | |B01=Determine the 10-year risk of coronary event using ANY of the following assessment tools:<br> | {{familytree | | | | | | | | | | | | B01 | | | | | | | | | | | | | | | | | | | | | | | | | | | | |B01=<div style="float: left; text-align: left; width: 18em; padding:1em;">Determine the 10-year risk of coronary event using ANY of the following assessment tools:<br> | ||
❑ Framingham Risk Assessment Tool (To be redirected to Framingham Risk Assessment Tool, click [http://cvdrisk.nhlbi.nih.gov/ here]) | ❑ Framingham Risk Assessment Tool (To be redirected to Framingham Risk Assessment Tool, click [http://cvdrisk.nhlbi.nih.gov/ here]) | ||
❑ Reynolds Risk Score (To be redirected to Reynolds Risk Score website, click [http://www.reynoldsriskscore.org/ here])}} | ❑ Reynolds Risk Score (To be redirected to Reynolds Risk Score website, click [http://www.reynoldsriskscore.org/ here])</div>}} | ||
{{familytree | | | | | |,|-|-|-|v|-|-|^|-|-|-|-|-|-|.| | | | | | | | | | | | | | | | | | | | | | |}} | {{familytree | | | | | |,|-|-|-|v|-|-|^|-|-|-|-|-|-|.| | | | | | | | | | | | | | | | | | | | | | |}} | ||
Line 98: | Line 98: | ||
{{familytree | | | | | |!| | | | | | | | |,|-|-|-|-|-|^|-|-|-|-|-|-|.| | | | | | | | | | | | | | |}} | {{familytree | | | | | |!| | | | | | | | |,|-|-|-|-|-|^|-|-|-|-|-|-|.| | | | | | | | | | | | | | |}} | ||
{{familytree | | | | | F01 | | | | | | | F02 | | | | | | | | | | | F03 | | | | | | | | | | | | | |F01='''Does the patient have ALL the following criteria for low-risk dyslipidemia during previous work-up?'''<br> | {{familytree | | | | | F01 | | | | | | | F02 | | | | | | | | | | | F03 | | | | | | | | | | | | | |F01=<div style="float: left; text-align: left; width: 18em; padding:1em;">'''Does the patient have ALL the following criteria for low-risk dyslipidemia during previous work-up?'''<br> | ||
❑ Low LDL-C < 100 mg/dL, '''AND''' <br> | ❑ Low LDL-C < 100 mg/dL, '''AND''' <br> | ||
Line 104: | Line 104: | ||
❑ HDL-C > 50 mg/dL, '''AND''' <br> | ❑ HDL-C > 50 mg/dL, '''AND''' <br> | ||
❑ Triglycerides < 150 mg/dL|F02=Adult patient|F03=Pediatric patient (age > 2 years)}} | ❑ Triglycerides < 150 mg/dL|F02=Adult patient|F03=Pediatric patient (age > 2 years)</div>}} | ||
{{familytree | | | |,|-|^|-|.| | | | | | |!| | | | | | | | | | | | |!| | | | | | | | | | | | | | |}} | {{familytree | | | |,|-|^|-|.| | | | | | |!| | | | | | | | | | | | |!| | | | | | | | | | | | | | |}} | ||
Line 132: | Line 132: | ||
{{familytree | L01 | | L02 | | L03 | | L04 | | L05 | | L06 | | | | | | | | | | | | | | | | | | | |L01=Screen every 5 years<br><span style="font-size:65%;color:red">More frequent screening is recommended for patients with risk factors for CAD (shown above)</span>|L02=Screen every 1 to 2 years<br><span style="font-size:65%;color:red">More frequent screening is recommended for patients with risk factors for CAD (shown above)</span>|L03=Screen annually|L04=Screen every 5 years<br><span style="font-size:65%;color:red">More frequent screening is recommended for patients with risk factors for CAD (shown above)</span>|L05=Screen every 1 to 2 years<br><span style="font-size:65%;color:red">More frequent screening is recommended for patients with risk factors for CAD (shown above)</span>|L06=Screen annually}} | {{familytree | L01 | | L02 | | L03 | | L04 | | L05 | | L06 | | | | | | | | | | | | | | | | | | | |L01=Screen every 5 years<br><span style="font-size:65%;color:red">More frequent screening is recommended for patients with risk factors for CAD (shown above)</span>|L02=Screen every 1 to 2 years<br><span style="font-size:65%;color:red">More frequent screening is recommended for patients with risk factors for CAD (shown above)</span>|L03=Screen annually|L04=Screen every 5 years<br><span style="font-size:65%;color:red">More frequent screening is recommended for patients with risk factors for CAD (shown above)</span>|L05=Screen every 1 to 2 years<br><span style="font-size:65%;color:red">More frequent screening is recommended for patients with risk factors for CAD (shown above)</span>|L06=Screen annually}} | ||
{{familytree/end}} | {{familytree/end}} | ||
==Complete Diagnostic Approach== | ==Complete Diagnostic Approach== |
Revision as of 15:48, 20 April 2015
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
Classification
Causes
Secondary causes of dyslipidemia may cause either an increase in total-cholesterol & low density lipoprotein-cholesterol (LDL-C) or an increase in total triglycerides & very low density lipoprotein cholesterol (VLDL-C). Common causes are listed below.
Increase in Total Cholesterol and LDL-C
- Hypothyroidism
- Nephrosis
- Dysgammaglobulinemia (systemic lupus erythematosus, multiple myeloma)
- Cholestatic hepatic diseases due to abnormal lipoproteins (e.g. primary biliary cirrhosis)
- Administration of protease inhibitors (treatment for HIV infection)
- Administration of progestin or anabolic steroids
Increase in Total Triglycerides and VLDL-C
- Chronic kidney disease
- Type 2 diabetes mellitus
- Obesity
- Excessive alcohol intake
- Hypothyroidism
- Administration of anti-hypertensive therapy (thiazide diuretics or B-blockers)
- Administration of corticosteroids
- Severe stress that increases endogenous corticosteroid concentration
- Elevated concentrations of estrogen (administration of oral (not transdermal) estrogen therapy, oral contraceptives, or pregnancy)
- Administration of protease inhibitors (treatment for HIV infection)
To view a comprehensive list of dyslipidemia causes, click here
Screening
Abbreviations: ASA: American society of anesthesiologists; BP: Blood Pressure; CCS: Canadian cardiovascular society; CrCl: Creatinine clearance; CXR: Chest X-ray; DNI: Do not intubate; DNR: Do not resuscitate; ECG: Electrocardiogram; eGFR: estimated glomerular filtration rate; HR:Heart rate; INR: International normalized ratio; LMWH: Low molecular weight heparin; LV: Left ventricle; LVED: Left ventricular ejection fraction; NOAC: Novel oral anticoagulant; NPO: Nothing per os; PMI: Point of maximal impulse; PT: Prothrombin time; RR: Respiratory rate; SpO2: Oxygen saturation; T: Temperature; VT: Ventricular tachycardia
Identify risk factors for CAD Major risk factors: ❑ Advanced age ❑ ↑ total serum cholesterol ❑ ↑ non-HDL-C (calculated by: total cholesterol minus HDL-C) ❑ ↑ LDL-C (either measured or calculated by: total cholesterol minus HDL-c minus (total triglycerides/5)) ❑ ↓ HDL-C ❑ Diabetes mellitus ❑ Hypertension ❑ Cigarette smoking ❑ Family history of CAD ❑ Obesity, especially abdominal ❑ Family history of hyperlipidemia ❑ Small, dense LDL-C ❑ ↑ Apo-B ❑ ↑ LDL particle number (measured by ApoB) ❑ Fasting/postprandial hypertriglyceridemia ❑ Polycystic ovarian syndrome ❑ Dyslipidemic triad ❑ ↑ lipoprotein ❑ ↑ clotting factors ❑ Inflamamtory markers (e.g. hsCRP or Lipoprotein-associated phospholipase A2 (Lp-PLA2) ❑ Hyperhomocysteinemia ❑ ApoE4 isoform | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
High (Framingham 10-year global risk > 20%) | Intermediate (Framingham 10-year global risk between 10% and 20%) | Lower (Framingham 10-year global risk < 10%) | Optimal (Framingham 10-year global risk < 10% with optimal levels or risk factors and heart-healthy lifestyle) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Does the patient have type 2 diabetes mellitus? | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Yes | No | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Does the patient have ALL the following criteria for low-risk dyslipidemia during previous work-up? ❑ Low LDL-C < 100 mg/dL, AND ❑ HDL-C > 50 mg/dL, AND | Adult patient | Pediatric patient (age > 2 years) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Yes. The patient has ALL of the criteria for low-risk dyslipidemia | Either unknown history of lipid profile or No, the patient does not have ALL of the criteria for low-risk dyslipidemia (at least 1 criterion is not met) | Does that patient have risk factors for CAD (listed above)? | Does the patient have risk factors for CAD (listed above)? | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Screen every 2 years | Screen annually | No | Yes | Yes | No | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Screen patient more frequently than patients with no risk factors based on clinical judgement (unknown optimal interval) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Male patient | Female patient | Screen every 3 to 5 years | Do not screen patient for dyslipidemia | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Age 20 to 45 years | Age > 45 to 65 years | Age > 65 years | Age 20 to 55 years | Age > 55 to 65 | Age > 65 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Screen every 5 years More frequent screening is recommended for patients with risk factors for CAD (shown above) | Screen every 1 to 2 years More frequent screening is recommended for patients with risk factors for CAD (shown above) | Screen annually | Screen every 5 years More frequent screening is recommended for patients with risk factors for CAD (shown above) | Screen every 1 to 2 years More frequent screening is recommended for patients with risk factors for CAD (shown above) | Screen annually | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||